26.09.2014 • NewsExxonMobilhydrocarbon fluidsOil

ExxonMobil Expands Specialty Hydrocarbons in Singapore, Antwerp

ExxonMobil Chemical plans to increase annual output of its high performance hydrocarbon fluids by about 10% through in Singapore and Antwerp up to 2016.

The US oil and petrochemicals major, which claims to be the leading producer of hydrocarbon fluids specifically formulated for resource extraction, industrial processing and a wide range of consumer applications, said the capacity upgrade is aimed at extending its supply capability in response to rapidly growing global demand.

Fluids marketing manager Declan Dixon said the expansion projects, which upgrade refining streams into specialty chemical products, build on other recently announced large investment projects at the Singapore and Antwerp facilities.

At Singapore, its largest integrated refining and chemical manufacturing site, ExxonMobil has expanded production to meet expected demand across the Asia Pacific region. At Antwerp, it has invested $2 billion over the past decade.

The Belgian hydrocarbon fluids expansion is aimed at strengthening the US company's integrated downstream and chemical portfolio in northwest Europe.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.